Decision to Grant Third EndoDrill® Patent in Japan
Cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”), developer of EndoDrill® – the world’s first market-cleared powered biopsy instrument for endoscopy – today announces that the Company has received a...
BiBBInstruments announces date for conversion of exercised warrants of series TO 1 into shares
BiBBInstruments AB (“BiBB” or the “Company”) announces that the Swedish Companies Registration Office has registered the shares subscribed for through the exercise of warrants of series TO 1 (“TO 1”). A...
BiBBInstruments AB announces outcome of subscription period for warrants of series TO 1
BiBBInstruments AB (”BiBB” or the ”Company”) today announces the outcome of the subscription period för warrants of series TO 1 (the ”Warrants” or ”TO 1”), which were issued in connection with...
BiBBInstruments AB – Receives intention of subscription regarding warrants of series TO 1 from management and board members
BiBBInstruments AB (“BiBB” or the “Company”) announces today that the Company has received intention of subscription from six members of its management and board of directors regarding the exercise of warrants...
BiBBInstruments AB: Publishes a letter from CEO Fredrik Lindblad
BiBBInstruments AB (“BiBB” or the “Company”) publishes a letter from the CEO, Fredrik Lindblad, due to the beginning of the subscription period for warrants of series TO 1. The CEO letter...
BiBBInstruments AB – The subscription period for warrants of series TO 1 begins today
The subscription period for the warrants of series TO 1 (“Warrants” or “TO 1”) that BiBBInstruments AB (“BiBB” or the “Company”) issued in connection with the Company’s rights issue of units,...
BiBBInstruments AB: The subscription price for warrants of series TO 1 set at SEK 3.25 per share
BiBBInstruments AB (“BiBB” or the “Company”) issued a total of 2,755,282 warrants of series TO 1 (“the Warrants” or “TO1”) in connection with the Company’s rights issue of units that was...
BiBB Receives U.S. Patent Notice of Allowance for EndoDrill®
BiBBInstruments AB (“BiBB” or the “Company”), a cancer diagnostics company developing EndoDrill® – the world’s first market-cleared powered biopsy instrument for endoscopy – today announced it has received a Notice of...
BiBB and TaeWoong Medical USA Sign Letter of Intent for U.S. Commercialization of EndoDrill® GI
BiBBInstruments AB (“BiBB” or “the Company”), developer of EndoDrill® – the world’s first market-cleared powered biopsy instrument for endoscopy – today announced that it has signed a non-binding Letter of Intent...
BiBB Receives Notice of Allowance for Additional EndoDrill Patent in China
The cancer diagnostics company BiBB Instruments AB (“BiBB” or “the Company”), which develops EndoDrill® – the world’s first market-cleared powered biopsy instrument for endoscopy – announces that the Company has received...
Successful Live Broadcasted Patient Case with EndoDrill® GI in Porto, Portugal
The cancer diagnostics company BiBBInstruments AB (“BiBB” or “the Company”), which develops EndoDrill® – the world’s first CE-marked electric-driven biopsy instrument for endoscopy – announces that EndoDrill® GI has been successfully...
First liver cases with EndoDrill GI performed in the USA
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”), the developer of EndoDrill® – the world’s first market-cleared powered biopsy instrument for endoscopy – announces that Dr. Mohammed Barawi, Medical...